The aim of this study is to elucidate the biogenetic modification of donor and recipient interleukin-28B (IL-28B) genotypes in\nliver graft biopsies after living donor liver transplantation (LDLT) for chronic hepatitis C virus- (HCV-) related, end-stage liver\ndisease. Fifty liver graft biopsies were collected from recipients during LDLT treatment for HCV-related, end-stage liver disease.\nDNA was extracted from all 50 liver tissues, and the IL-28B single-nucleotide polymorphisms (SNPs) rs8099917 and rs12979860\nwere studied for allelic discrimination by real-time PCR analysis. Blood samples were obtained from donors and recipients on\npostoperative day 0 (POD0), POD7, and POD30. We randomly selected five liver biopsies and isolated the hepatocytes by laser\ncapture microdissection (LCM) to evaluate genotype modifications resulting from LDLT. After LDLT, the IL-28B SNP rs8099917\nwas identified not only in the liver graft biopsies and donors� sera (TT = 41 : 43; GT = 9 : 5; GG = 0 : 2), but also in liver graft biopsies\nand recipients� sera on POD0 (TT = 41 :44; GT = 9:4; GG = 0:2), POD7 (TT = 41 :30; GT = 9: 18;GG = 0:2), and POD30 (TT =\n41 : 29; GT = 9 : 19; GG = 0 : 2). A significant difference was observed between the rs8099917 allele frequencies of liver graft biopsies\nand recipients� sera on POD30 (
Loading....